Klotho Neurosciences, Inc. (NASDAQ:KLTO) Short Interest Update

Klotho Neurosciences, Inc. (NASDAQ:KLTO) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 1,033,627 shares, an increase of 163.8% from the January 15th total of 391,815 shares. Based on an average daily trading volume, of 590,981 shares, the days-to-cover ratio is currently 1.7 days. Currently, 1.6% of the company’s stock are sold short. Currently, 1.6% of the company’s stock are sold short. Based on an average daily trading volume, of 590,981 shares, the days-to-cover ratio is currently 1.7 days.

Institutional Investors Weigh In On Klotho Neurosciences

Hedge funds have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in shares of Klotho Neurosciences in the 2nd quarter valued at about $26,000. Geode Capital Management LLC raised its position in Klotho Neurosciences by 51.8% during the fourth quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock worth $142,000 after acquiring an additional 167,905 shares during the period. Finally, Brummer Multi Strategy AB acquired a new stake in shares of Klotho Neurosciences in the fourth quarter valued at about $175,000. 20.07% of the stock is owned by hedge funds and other institutional investors.

Klotho Neurosciences Trading Down 6.1%

Shares of KLTO stock traded down $0.01 during mid-day trading on Thursday, reaching $0.22. The stock had a trading volume of 298,501 shares, compared to its average volume of 586,029. Klotho Neurosciences has a 1-year low of $0.11 and a 1-year high of $3.91. The firm has a market cap of $15.92 million, a price-to-earnings ratio of -0.68 and a beta of 10.27. The business’s fifty day moving average is $0.33 and its 200-day moving average is $0.51.

Klotho Neurosciences (NASDAQ:KLTO) last issued its earnings results on Thursday, November 13th. The company reported ($0.05) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Klotho Neurosciences in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

About Klotho Neurosciences

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.